Drug Type Small molecule drug |
Synonyms Cannabidiol/delta-9-tetrahydrocannabivarin, Cannabidiol/tetrahydrocannabivarin-9, Tetrahydrocannabivarol-9/cannabidiol + [3] |
Target |
Action antagonists |
Mechanism CB1 antagonists(Cannabinoid CB1 receptor antagonists), CB2 antagonists(Cannabinoid CB2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H30O2 |
InChIKeyQHMBSVQNZZTUGM-ZWKOTPCHSA-N |
CAS Registry13956-29-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyslipidemias | Phase 2 | United Kingdom | 01 Oct 2011 | |
Diabetes Mellitus, Type 2 | Phase 2 | United Kingdom | - | |
Diabetes Mellitus, Type 2 | Phase 2 | - | - | |
Metabolic Syndrome | Phase 2 | United Kingdom | - | |
Metabolic Syndrome | Phase 2 | - | - | |
Obesity | Phase 2 | United Kingdom | - |
Not Applicable | 42 | Medical Cannabis | eklzqlbpsn(bwtzgnxqgr) = AE were reported in 40%, and two discontinued because of AE. The most common side effects were fatigue, somnolence, nausea, and dizziness hqpeyenexd (jksnjntath ) | Positive | 09 Apr 2019 | ||
Phase 2 | 2 | (GWP42003 : GWP42004 (40:1)) | frajflblkw = vwmqpsuxim oiqmkcypqo (dahslhbfjk, cqlrugctlf - izavaiplgz) View more | - | 01 Nov 2013 | ||
Placebo (Placebo) | frajflblkw = jnqakljrdn oiqmkcypqo (dahslhbfjk, uxbksfmebw - afbbgmnwvz) View more |